Literature DB >> 12752492

Type 2 diabetes presenting as diabetic ketoacidosis in adolescence.

J Valabhji1, M Watson, J Cox, C Poulter, C Elwig, R S Elkeles.   

Abstract

We report two black adolescent subjects who presented with diabetic ketoacidosis, but who lacked autoimmune markers and demonstrated clinical and biochemical characteristics more typical of Type 2 diabetes, including obesity, acanthosis nigricans, positive family history for Type 2 diabetes, and Type 2 diabetic dyslipidaemia. Subsequent to acute presentation, insulin was discontinued in both subjects and excellent glycaemic control was achieved with metformin therapy alone. Four months following acute presentation, both had adequate C-peptide responses to intravenous glucagon. Type 2 diabetes can present as diabetic ketoacidosis in obese adolescent subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752492     DOI: 10.1046/j.1464-5491.2003.00942.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes?

Authors:  Joey C Low; Eric I Felner; Andrew B Muir; Milton Brown; Margalie Dorcelet; Limin Peng; Guillermo E Umpierrez
Journal:  Prim Care Diabetes       Date:  2012-01-09       Impact factor: 2.459

2.  AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

Authors:  Hans Ludwig Schäfer; Wolfgang Linz; Eugen Falk; Maike Glien; Heiner Glombik; Marcus Korn; Wolfgang Wendler; Andreas W Herling; Hartmut Rütten
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

3.  Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs.

Authors:  R Karoli; J Fatima; T Salman; S Sandhu; R Shankar
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

4.  Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Authors:  Mukul R Jain; Suresh R Giri; Chitrang Trivedi; Bibhuti Bhoi; Akshyaya Rath; Geeta Vanage; Purvi Vyas; Ramchandra Ranvir; Pankaj R Patel
Journal:  Pharmacol Res Perspect       Date:  2015-05-04

5.  Risk Factors of Ketosis in Obese Ketosis-Prone Diabetic Patients: A Case-Control Study.

Authors:  Li Shi; Liang Zhou; Juan Liu; Yang Ding; Xin-Hua Ye; Jin-Luo Cheng
Journal:  Diabetes Ther       Date:  2020-03-13       Impact factor: 2.945

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.